The administration of an anti-C5 monoclonal antibody has been proven to be effective in patients with complement dysregulation hemolytic uremic syndrome and NZB/WF1 mouse model by blocking the development of C5b-9, which led to the retardation of glomerular damage and an increase in survival, respectively [18, 19]. This evidence concerns the gene C5 and hemolytic-uremic syndrome.